# Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

> **NCT00354523** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor
- Thyroid Cancer

## Interventions

- **DRUG:** Capecitabine (Xeloda)
- **DRUG:** DTIC-Dome (Dacarbazine)
- **DRUG:** Gleevec (Imatinib Mesylate)

## Key facts

- **NCT ID:** NCT00354523
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2006-11
- **Final completion:** 2013-08
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study closed following Phase I portion, insufficient activity to continue to Phase II.
- **Last updated:** 2014-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354523, "Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00354523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*